Sign in
Not yet recruitingPhase 1

A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.

Key facts

Who runs it
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
124 people, planned
Starts
20 Nov 2026
Expected to end
30 Mar 2028
Type of study
Interventional, 11 groups
Treatments tested
  • QLS2406-1 injection
  • Placebo
Record updated
16 November 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Part A; Aged 18 to 55 years (inclusive) at screening, with no restriction on gender; At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and BMI ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive); Subjects are in good health as comprehensively assessed by the Investigator, with no clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasonography, clinical laboratory tests, etc; Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy; Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written informed consent
  • Part B; Aged 18 to 65 years (inclusive) at screening, regardless of gender; BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive); Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy; Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent; Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported)

Who cannot take part

  • History of any severe clinical disease, or clinically significant cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or malignancy within 24 weeks prior to randomization
  • History of hypoglycemia within 24 weeks prior to randomization
  • Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications
  • Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc
  • Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study
  • Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology
  • History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg
  • 12-lead ECG at screening with heart rate >100 bpm or <50 bpm, second- or third-degree atrioventricular block, prolonged QTcF (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome
  • Use of any drugs, products or non-pharmacologic therapies (other than investigational product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening
  • Any screening laboratory value meeting any of the following criteria, including but not limited to:; Serum amylase or serum lipase >1.5 × upper limit of normal (ULN); Fasting glucose abnormality or glycated hemoglobin (HbA1c) ≥6.5%; Calcitonin >20 ng/L; TG ≥5.65 mmol/L (500 mg/dL); E value ≥12.0 kPa (FibroScan) (Part B only)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

About the trial

What the trial wants to find out

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.

The 11 groups in the trial

  • Part A Cohort 1Treatment being tested

    SAD dose 1

    Treatment: QLS2406-1 injection and Placebo

  • Part A Cohort 2Treatment being tested

    SAD dose 2

    Treatment: QLS2406-1 injection and Placebo

  • Part A Cohort 3Treatment being tested

    SAD dose 3

    Treatment: QLS2406-1 injection and Placebo

  • Part A Cohort 4Treatment being tested

    SAD dose 4

    Treatment: QLS2406-1 injection and Placebo

  • Part A Cohort 5Treatment being tested

    SAD dose 5

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 1Treatment being tested

    MAD dose 1

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 2Treatment being tested

    MAD dose 2

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 3Treatment being tested

    MAD dose 3

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 4Treatment being tested

    MAD dose 4

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 5Treatment being tested

    MAD dose 5

    Treatment: QLS2406-1 injection and Placebo

  • Part B Cohort 6Treatment being tested

    MAD dose 6

    Treatment: QLS2406-1 injection and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
Criteria questions
Built from NCT07937787, who can take part
Record updated
16 November 2026